Xiangxue Pharmaceutical Co akcijos akcijų analizė | Akcijų kaina | Naujienos | 300147.SZ | CNE100000Y92 |

Data	Xiangxue Pharmaceutical Co Pajamos	Xiangxue Pharmaceutical Co EBIT	Xiangxue Pharmaceutical Co Pelnas
2023	2,30 mlrd. CNY	39,74 mln. CNY	−388,96 mln. CNY
2022	2,19 mlrd. CNY	−181,89 mln. CNY	−533,16 mln. CNY
2021	2,97 mlrd. CNY	−2,24 mln. CNY	−688,47 mln. CNY
2020	3,07 mlrd. CNY	389,30 mln. CNY	98,40 mln. CNY
2019	2,79 mlrd. CNY	263,40 mln. CNY	76,50 mln. CNY
2018	2,50 mlrd. CNY	317,20 mln. CNY	56,40 mln. CNY
2017	2,19 mlrd. CNY	115,30 mln. CNY	65,90 mln. CNY
2016	1,86 mlrd. CNY	118,10 mln. CNY	66,00 mln. CNY
2015	1,46 mlrd. CNY	217,40 mln. CNY	177,30 mln. CNY
2014	1,52 mlrd. CNY	255,30 mln. CNY	196,80 mln. CNY
2013	1,26 mlrd. CNY	232,10 mln. CNY	158,20 mln. CNY
2012	801,00 mln. CNY	147,00 mln. CNY	107,20 mln. CNY
2011	616,10 mln. CNY	102,20 mln. CNY	83,50 mln. CNY
2010	513,40 mln. CNY	101,30 mln. CNY	74,20 mln. CNY
2009	378,60 mln. CNY	71,40 mln. CNY	51,00 mln. CNY
2008	294,80 mln. CNY	41,70 mln. CNY	35,90 mln. CNY
2007	258,30 mln. CNY	37,10 mln. CNY	30,80 mln. CNY

	Pajamos	EBIT	Pelnas
2007	258,30 mln. CNY	37,10 mln. CNY	30,80 mln. CNY
2008	294,80 mln. CNY	41,70 mln. CNY	35,90 mln. CNY
2009	378,60 mln. CNY	71,40 mln. CNY	51,00 mln. CNY
2010	513,40 mln. CNY	101,30 mln. CNY	74,20 mln. CNY
2011	616,10 mln. CNY	102,20 mln. CNY	83,50 mln. CNY
2012	801,00 mln. CNY	147,00 mln. CNY	107,20 mln. CNY
2013	1,26 mlrd. CNY	232,10 mln. CNY	158,20 mln. CNY
2014	1,52 mlrd. CNY	255,30 mln. CNY	196,80 mln. CNY
2015	1,46 mlrd. CNY	217,40 mln. CNY	177,30 mln. CNY
2016	1,86 mlrd. CNY	118,10 mln. CNY	66,00 mln. CNY
2017	2,19 mlrd. CNY	115,30 mln. CNY	65,90 mln. CNY
2018	2,50 mlrd. CNY	317,20 mln. CNY	56,40 mln. CNY
2019	2,79 mlrd. CNY	263,40 mln. CNY	76,50 mln. CNY
2020	3,07 mlrd. CNY	389,30 mln. CNY	98,40 mln. CNY
2021	2,97 mlrd. CNY	−2,24 mln. CNY	−688,47 mln. CNY
2022	2,19 mlrd. CNY	−181,89 mln. CNY	−533,16 mln. CNY
2023	2,30 mlrd. CNY	39,74 mln. CNY	−388,96 mln. CNY

2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0,26	0,29	0,38	0,51	0,62	0,80	1,26	1,52	1,46	1,86	2,19	2,50	2,79	3,07	2,97	2,19	2,30
-	13,95	28,57	35,71	20,08	30,03	57,43	20,86	−3,94	27,19	17,45	14,49	11,26	10,27	−3,32	−26,36	5,12
46,12	51,02	50,53	46,20	45,94	47,69	41,00	41,60	42,62	31,53	29,49	36,46	31,59	32,29	24,95	24,28	32,32
119,00	150,00	191,00	237,00	283,00	382,00	517,00	634,00	624,00	587,00	645,00	913,00	880,00	992,00	741,00	531,00	743,00
37,00	41,00	71,00	101,00	102,00	147,00	232,00	255,00	217,00	118,00	115,00	317,00	263,00	389,00	−2,00	−181,00	39,00
14,34	13,95	18,78	19,69	16,56	18,35	18,40	16,73	14,82	6,34	5,26	12,66	9,44	12,66	−0,07	−8,28	1,70
30,00	35,00	51,00	74,00	83,00	107,00	158,00	196,00	177,00	66,00	65,00	56,00	76,00	98,00	−688,00	−533,00	−388,00
-	16,67	45,71	45,10	12,16	28,92	47,66	24,05	−9,69	−62,71	−1,52	−13,85	35,71	28,95	−802,04	−22,53	−27,20
396,90	396,90	396,90	450,80	602,70	608,60	615,60	609,60	661,50	660,20	661,50	661,50	637,60	661,50	661,36	658,22	661,28
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	0	0	−688,00	0	−533,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	188,00	0	238,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	5,00	0	−16,00
−29,00	−75,00	−91,00	−86,00	−113,00	−222,00	−181,00	−386,00	−322,00	−487,00	−365,00	−566,00	−491,00	−377,00	118,00	−657,00	−436,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	662,00	0	326,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
−29,00	−34,00	−42,00	−54,00	−72,00	−75,00	−123,00	−117,00	−130,00	−135,00	−115,00	−105,00	−90,00	−111,00	116,00	−116,00	−65,00
138,00	55,00	46,00	45,00	29,00	118,00	328,00	165,00	159,00	198,00	109,00	91,00	83,00	257,00	257,00	257,00	227,00
−144,00	−137,00	−52,00	−56,00	−230,00	−418,00	−318,00	−243,00	−277,00	−1 966,00	−777,00	−495,00	−661,00	−707,00	−562,00	−562,00	−367,00
−93,00	−82,00	−52,00	−56,00	−368,00	−451,00	−578,00	−503,00	−612,00	−2 569,00	−673,00	219,00	848,00	−1 238,00	−112,00	−112,00	379,00
0,05	0,05	0	0	−0,14	−0,03	−0,26	−0,26	−0,34	−0,60	0,10	0,72	1,51	−0,53	0,45	0,45	0,75
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0,01	0,02	0,03	0,12	0,01	0,86	−0,16	0,04	−0,63	2,34	1,12	−0,53	−0,90	1,20	−0,27	−0,68	−0,49
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
−0,01	0,01	0,06	1,07	−0,02	0,84	−0,29	−0,11	0,79	2,22	0,96	−0,76	−1,03	1,12	−0,45	−0,45	−0,65
−0,00	0,04	0,05	1,01	0,02	0,06	0,02	−0,00	1,56	0,03	0,02	−0,02	0,11	0,13	0,04	0,45	0,02
−17,00	−42,00	−11,00	−65,00	−54,00	−80,00	−147,00	−150,00	−135,00	−157,00	−172,00	−207,00	−239,00	−204,00	−216,00	−216,00	−175,00
0,23	0,15	0,24	1,24	−0,15	0,92	0,09	0,22	0,95	0,67	0,99	0,32	0,56	0,89	0,73	0,73	0,68
−6,70	−82,00	−6,70	−11,40	−201,10	−299,20	9,90	−78,30	−117,10	−1 767,50	−668,40	−404,30	−578,10	−450,20	−305,18	−305,18	−139,89
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Xiangxue Pharmaceutical Co Bruto marža	Xiangxue Pharmaceutical Co Pelnas-martža	Xiangxue Pharmaceutical Co EBIT marža	Xiangxue Pharmaceutical Co Pelnas-martža
2023	32,33 %	1,73 %	−16,92 %
2022	24,32 %	−8,32 %	−24,38 %
2021	24,96 %	−0,08 %	−23,18 %
2020	32,31 %	12,67 %	3,20 %
2019	31,61 %	9,45 %	2,75 %
2018	36,46 %	12,67 %	2,25 %
2017	29,50 %	5,27 %	3,01 %
2016	31,52 %	6,34 %	3,54 %
2015	42,64 %	14,84 %	12,11 %
2014	41,63 %	16,75 %	12,91 %
2013	41,06 %	18,40 %	12,54 %
2012	47,73 %	18,35 %	13,38 %
2011	46,03 %	16,59 %	13,55 %
2010	46,30 %	19,73 %	14,45 %
2009	50,45 %	18,86 %	13,47 %
2008	51,15 %	14,15 %	12,18 %
2007	46,30 %	14,36 %	11,92 %

	Bruto marža	EBIT marža	Pelnas-martža
2007	46,30 %	14,36 %	11,92 %
2008	51,15 %	14,15 %	12,18 %
2009	50,45 %	18,86 %	13,47 %
2010	46,30 %	19,73 %	14,45 %
2011	46,03 %	16,59 %	13,55 %
2012	47,73 %	18,35 %	13,38 %
2013	41,06 %	18,40 %	12,54 %
2014	41,63 %	16,75 %	12,91 %
2015	42,64 %	14,84 %	12,11 %
2016	31,52 %	6,34 %	3,54 %
2017	29,50 %	5,27 %	3,01 %
2018	36,46 %	12,67 %	2,25 %
2019	31,61 %	9,45 %	2,75 %
2020	32,31 %	12,67 %	3,20 %
2021	24,96 %	−0,08 %	−23,18 %
2022	24,32 %	−8,32 %	−24,38 %
2023	32,33 %	1,73 %	−16,92 %

Data	Xiangxue Pharmaceutical Co Pardavimai vienai akcijai	Xiangxue Pharmaceutical Co EBIT vienai akcijai	Xiangxue Pharmaceutical Co Pelnas vienai akcijai
2023	3,48 CNY	0,06 CNY	−0,59 CNY
2022	3,32 CNY	−0,28 CNY	−0,81 CNY
2021	4,49 CNY	−0,00 CNY	−1,04 CNY
2020	4,64 CNY	0,59 CNY	0,15 CNY
2019	4,37 CNY	0,41 CNY	0,12 CNY
2018	3,79 CNY	0,48 CNY	0,09 CNY
2017	3,31 CNY	0,17 CNY	0,10 CNY
2016	2,82 CNY	0,18 CNY	0,10 CNY
2015	2,21 CNY	0,33 CNY	0,27 CNY
2014	2,50 CNY	0,42 CNY	0,32 CNY
2013	2,05 CNY	0,38 CNY	0,26 CNY
2012	1,32 CNY	0,24 CNY	0,18 CNY
2011	1,02 CNY	0,17 CNY	0,14 CNY
2010	1,14 CNY	0,22 CNY	0,16 CNY
2009	0,95 CNY	0,18 CNY	0,13 CNY
2008	0,74 CNY	0,11 CNY	0,09 CNY
2007	0,65 CNY	0,09 CNY	0,08 CNY

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2007	0,65 CNY	0,09 CNY	0,08 CNY
2008	0,74 CNY	0,11 CNY	0,09 CNY
2009	0,95 CNY	0,18 CNY	0,13 CNY
2010	1,14 CNY	0,22 CNY	0,16 CNY
2011	1,02 CNY	0,17 CNY	0,14 CNY
2012	1,32 CNY	0,24 CNY	0,18 CNY
2013	2,05 CNY	0,38 CNY	0,26 CNY
2014	2,50 CNY	0,42 CNY	0,32 CNY
2015	2,21 CNY	0,33 CNY	0,27 CNY
2016	2,82 CNY	0,18 CNY	0,10 CNY
2017	3,31 CNY	0,17 CNY	0,10 CNY
2018	3,79 CNY	0,48 CNY	0,09 CNY
2019	4,37 CNY	0,41 CNY	0,12 CNY
2020	4,64 CNY	0,59 CNY	0,15 CNY
2021	4,49 CNY	−0,00 CNY	−1,04 CNY
2022	3,32 CNY	−0,28 CNY	−0,81 CNY
2023	3,48 CNY	0,06 CNY	−0,59 CNY

	Akcijų skaičius
2007	396,90 mln. Aktien
2008	396,90 mln. Aktien
2009	396,90 mln. Aktien
2010	450,80 mln. Aktien
2011	602,70 mln. Aktien
2012	608,60 mln. Aktien
2013	615,60 mln. Aktien
2014	609,60 mln. Aktien
2015	661,50 mln. Aktien
2016	660,20 mln. Aktien
2017	661,50 mln. Aktien
2018	661,50 mln. Aktien
2019	637,60 mln. Aktien
2020	661,50 mln. Aktien
2021	661,36 mln. Aktien
2022	658,22 mln. Aktien
2023	661,28 mln. Aktien

Data	Xiangxue Pharmaceutical Co Dividendas
2020	0,05 CNY
2019	0,03 CNY
2018	0,03 CNY
2016	0,12 CNY
2015	0,11 CNY
2014	0,10 CNY
2013	0,12 CNY
2012	0,10 CNY
2011	0,07 CNY

	Dividendas	Dividenda (įvertinimas)
2007	0 CNY	0 CNY
2008	0 CNY	0 CNY
2009	0 CNY	0 CNY
2010	0 CNY	0 CNY
2011	0,07 CNY	0 CNY
2012	0,10 CNY	0 CNY
2013	0,12 CNY	0 CNY
2014	0,10 CNY	0 CNY
2015	0,11 CNY	0 CNY
2016	0,12 CNY	0 CNY
2017	0 CNY	0 CNY
2018	0,03 CNY	0 CNY
2019	0,03 CNY	0 CNY
2020	0,05 CNY	0 CNY
2021	0 CNY	0 CNY
2022	0 CNY	0 CNY
2023	0 CNY	0 CNY

Data	Xiangxue Pharmaceutical Co Išmokėjimo santykis
2023	30,50 %
2022	29,95 %
2021	30,86 %
2020	30,67 %
2019	28,33 %
2018	33,59 %
2017	30,86 %
2016	120,00 %
2015	41,39 %
2014	31,84 %
2013	45,50 %
2012	54,78 %
2011	52,86 %
2010	30,86 %
2009	30,86 %
2008	30,86 %
2007	30,86 %

	Išmokėjimo santykis
2007	30,86 %
2008	30,86 %
2009	30,86 %
2010	30,86 %
2011	52,86 %
2012	54,78 %
2013	45,50 %
2014	31,84 %
2015	41,39 %
2016	120,00 %
2017	30,86 %
2018	33,59 %
2019	28,33 %
2020	30,67 %
2021	30,86 %
2022	29,95 %
2023	30,50 %

Data	EPS-prognozė	EPS-Faktinis	Pranešimo ketvirtis
2015-06-30	0,18 CNY	0,10 CNY (−44,99 %)	2015 Q2
2014-12-31	0,16 CNY	0,07 CNY (−53,09 %)	2014 Q4
2014-09-30	0,18 CNY	0,10 CNY (−43,43 %)	2014 Q3
2014-06-30	0,15 CNY	0,11 CNY (−24,10 %)	2014 Q2
2013-12-31	0,08 CNY	0,08 CNY (7,22 %)	2013 Q4
2013-09-30	0,10 CNY	0,08 CNY (−14,23 %)	2013 Q3
2013-06-30	0,09 CNY	0,04 CNY (−49,12 %)	2013 Q2
2012-12-31	0,12 CNY	0,04 CNY (−61,34 %)	2012 Q4

%	Pavadinimas	Akcijos	Pokytis	Data
4,07 %	Guangzhou Luogang Water Supply Co., Ltd.	26 832 260	0	2023-09-30
22,68 %	Guangzhou Kunlun Investment Co., Ltd.	149 409 921	0	2023-09-30
0,92 %	CITIC Securities Co., Ltd. (Asset Management)	6 086 098	2 766 802	2023-09-30
0,62 %	Liu (Wuxiong)	4 067 483	21 700	2023-09-30
0,38 %	Ye (Xiao Zhao)	2 503 800	0	2023-09-30
0,36 %	Liao (Tingbin)	2 380 158	46 000	2023-09-30
0,31 %	China Universal Asset Management Co., Ltd.	2 022 500	25 000	2023-09-30
0,23 %	Huang (Xueying)	1 516 660	18 000	2023-09-30
0,19 %	China Southern Asset Management Co. Ltd.	1 248 800	1 248 800	2023-06-30
0,16 %	Penghua Fund Management Co., Ltd.	1 052 300	367 200	2023-06-30
0,07 %	GF Fund Management Co., Ltd.	474 100	−361 800	2023-12-31
0,07 %	The Vanguard Group, Inc.	460 600	0	2024-03-31
0,06 %	Zeng (Lun)	394 137	0	2023-06-30
0,05 %	Kang (Zhiying)	305 787	0	2023-06-30
0,04 %	Huang (Weihua)	247 484	0	2023-06-30
0,03 %	Xu (Li)	201 701	0	2023-06-30
0,03 %	Mo (Ziyu)	181 255	0	2023-06-30
0,03 %	Huatai-PineBridge Fund Management Co., Ltd.	165 800	23 500	2023-06-30
0,02 %	Tan (Wenhui)	133 031	0	2023-06-30
0,01 %	Hwabao WP Fund Management Co., Ltd.	91 600	91 600	2023-06-30
0,01 %	Yinhua Fund Management Co., Ltd.	79 000	79 000	2023-06-30
0,01 %	Tianhong Asset Management Co., Ltd.	71 600	71 600	2023-06-30
0,01 %	Chen (Wenjin)	60 000	0	2023-06-30
0,00 %	INVESCO Great Wall Fund Management Co. Ltd.	28 700	28 700	2023-06-30
0,00 %	Shanghai Haitong Securities Asset Management Ltd.	27 800	−15 500	2023-12-31
0,00 %	Niu (Xiaoyan)	15 000	0	2023-06-30
0,00 %	Sealand Securities Co., Ltd.	12 400	−69 700	2023-06-30
0,00 %	Vanguard Investments Australia Ltd.	2 277	4	2024-02-29
0,00 %	Lion Fund Management Co., Ltd.	900	900	2023-06-30
0 %	China Huarong Asset Management Co., Ltd.	0	−60 000	2023-06-30
0 %	Rongtong Fund Management Co., Ltd.	0	−11 200	2023-12-31

Pavadinimas	Santykis	Dviejų savaičių koreliacija	Vieno mėnesio koreliacija	Trymėnesio koreliacija	Šešių mėnesių koreliacija	Vienmečio koreliacija	Dviejų metų koreliacija
China Meheco Group A	TiekėjasKlientas	0,87	0,75	0,45	0,24	0,12	0,10
Zhangzhou Pientzehuang A	TiekėjasKlientas	0,40	0,24	0,31	0,01	0,04	-0,68
Guangzhou Baiyunshan H	TiekėjasKlientas	0,30	0,49	0,11	0,45	0,61	0,06
Athenex	TiekėjasKlientas	-0,32	-0,45	0,80	0,14	0,38	0,85

What values and corporate philosophy does Xiangxue Pharmaceutical Co represent?

Xiangxue Pharmaceutical Co Ltd represents values of innovation, integrity, and sustainability in the pharmaceutical industry. With a strong corporate philosophy focused on research and development, Xiangxue Pharmaceutical strives to provide high-quality and affordable healthcare solutions to improve the lives of people globally. The company's commitment to technological advancements and scientific excellence enables them to develop cutting-edge pharmaceutical products and treatments. Xiangxue Pharmaceutical embraces a customer-centric approach, ensuring the well-being of patients and addressing unmet medical needs. By adhering to ethical business practices and promoting social responsibility, Xiangxue Pharmaceutical serves as a trusted partner in the healthcare sector.

In which countries and regions is Xiangxue Pharmaceutical Co primarily present?

Xiangxue Pharmaceutical Co Ltd is primarily present in China.

What significant milestones has the company Xiangxue Pharmaceutical Co achieved?

Xiangxue Pharmaceutical Co Ltd has achieved several significant milestones. The company has successfully developed and launched a range of innovative pharmaceutical products, gaining recognition within the industry. Xiangxue Pharmaceutical Co Ltd has also established strategic partnerships with leading international pharmaceutical companies, expanding its global reach and collaboration opportunities. Additionally, the company has shown consistent growth with its financial performance, demonstrating strong market presence and investor confidence. Overall, Xiangxue Pharmaceutical Co Ltd has made notable advancements, solidifying its position as a prominent player in the pharmaceutical sector.

What is the history and background of the company Xiangxue Pharmaceutical Co?

Xiangxue Pharmaceutical Co Ltd is a leading Chinese pharmaceutical company with a rich history and background. Founded in 1986, the company has grown into a renowned player in the healthcare industry. Xiangxue Pharmaceutical focuses on research, development, manufacturing, and marketing of innovative drugs, particularly in the fields of antibiotics, anti-tumor agents, and cardiovascular drugs. With its commitment to quality and innovation, the company has gained recognition both domestically and internationally. Xiangxue Pharmaceutical's dedication to improving human health and providing cutting-edge medical solutions sets it apart in the pharmaceutical sector.

Who are the main competitors of Xiangxue Pharmaceutical Co in the market?

The main competitors of Xiangxue Pharmaceutical Co Ltd in the market include companies such as Jiangsu Hengrui Medicine Co Ltd, Shanghai Fosun Pharmaceutical Group Co Ltd, and Beijing SL Pharmaceutical Co Ltd. These companies play a significant role in the pharmaceutical industry and compete with Xiangxue Pharmaceutical Co Ltd in terms of product offerings, market share, and innovation. It is essential for Xiangxue Pharmaceutical Co Ltd to continuously evaluate and differentiate its products and services to maintain a competitive edge with these prominent market players.

In which industries is Xiangxue Pharmaceutical Co primarily active?

Xiangxue Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry. With a focus on research, development, manufacturing, and distribution of pharmaceutical products, Xiangxue Pharmaceutical plays a pivotal role in improving healthcare outcomes. Their expertise spans across various therapeutic areas, including cardiovascular, respiratory, gastrointestinal, and geriatric medicines. By continuously innovating and adhering to strict quality standards, Xiangxue Pharmaceutical strives to deliver safe and effective treatments to patients worldwide. With their strong presence in the pharmaceutical sector, Xiangxue Pharmaceutical remains committed to advancing healthcare and making a positive impact on people's lives.

What is the business model of Xiangxue Pharmaceutical Co?

The business model of Xiangxue Pharmaceutical Co Ltd revolves around the research, development, manufacturing, and sales of pharmaceutical products. As a leading pharmaceutical company, Xiangxue Pharmaceutical focuses on areas such as innovative drug development, generics, and biological products. The company's business model emphasizes a comprehensive approach to healthcare, including both traditional Chinese medicine and Western medicine. Xiangxue Pharmaceutical Co Ltd seeks to provide high-quality, affordable medications and medical solutions to improve public health.

Koks yra Xiangxue Pharmaceutical Co 2024 KGV?

P/E santykio šiuo metu Xiangxue Pharmaceutical Co apskaičiuoti negalima.

Koks Xiangxue Pharmaceutical Co 2024 KUV?

KUV šiuo metu negali būti apskaičiuotas Xiangxue Pharmaceutical Co.

Koks yra Xiangxue Pharmaceutical Co AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis Xiangxue Pharmaceutical Co yra 2/10.

Koks yra Xiangxue Pharmaceutical Co 2024 pajamų dydis?

Pajamos šiuo metu negali būti apskaičiuotos Xiangxue Pharmaceutical Co.

Kokia yra Xiangxue Pharmaceutical Co 2024 pelnas?

Pelnas šiuo metu negali būti apskaičiuotas Xiangxue Pharmaceutical Co.

Ką daro Xiangxue Pharmaceutical Co?

Xiangxue Pharmaceutical Co Ltd is a Chinese company that specializes in the manufacturing and sale of pharmaceuticals and health products. The company was founded in 1997 and has been listed on the Shanghai Stock Exchange since 2003. The business model of Xiangxue Pharmaceutical includes several divisions, including the development, manufacturing, and marketing of pharmaceutical products, natural remedies, as well as dietary supplements and medical devices. The company produces a variety of drugs, including antibiotics, antiviral medications, drugs for the treatment of cancer and cardiovascular diseases. In addition, Xiangxue Pharmaceutical is also involved in research and development and has introduced several groundbreaking products to the market in recent years. An example is the medication "XKS," which is used for the treatment of liver diseases. It was developed by Xiangxue Pharmaceutical and is the first Chinese drug to be approved by the European Medicines Agency. In the field of natural health products, the company offers an extensive range of products, including herbal extracts, traditional Chinese medicine products, and other natural remedies. These products are distributed in China and internationally and are popular among consumers seeking a natural alternative to traditional Western medicine. Xiangxue Pharmaceutical also utilizes advanced technologies to produce innovative and effective products. The company continuously invests in research and development and collaborates closely with universities and research institutions to develop new products and technologies. The company aims to be a leader in the field of modern medicine and natural health products in the Chinese and international markets. To achieve this goal, Xiangxue Pharmaceutical has established a strong presence in the market and continuously works on improving its business operations. Overall, Xiangxue Pharmaceutical's business model is well positioned to succeed in the Chinese and international markets. By combining innovative products, advanced technology, and effective marketing, the company has gained a strong position in the healthcare market and is expected to continue to expand in the future.

Kokia yra Xiangxue Pharmaceutical Co dividendė?

Xiangxue Pharmaceutical Co moka dividendą 0 CNY, kuris yra paskirstytas per išmokas per metus.

Kiek kartų Xiangxue Pharmaceutical Co moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota Xiangxue Pharmaceutical Co arba įmonė dividendų nemoka.

Kas yra Xiangxue Pharmaceutical Co ISIN?

Xiangxue Pharmaceutical Co ISIN yra CNE100000Y92.

Kas yra Xiangxue Pharmaceutical Co Tickeris?

Xiangxue Pharmaceutical Co akcijų simbolis yra 300147.SZ.

Kiek dividendų moka Xiangxue Pharmaceutical Co?

Per paskutinius 12 mėnesių Xiangxue Pharmaceutical Co išmokėjo dividendą, kurios dydis siekė 0,05 CNY . Tai atitinka maždaug 1,36 % dividendų grąžą. Artimiausiems 12 mėnesiams Xiangxue Pharmaceutical Co tikėtina išmokės dividendus, kurie sudarys 0 CNY.

Kokia yra Xiangxue Pharmaceutical Co dividendų grąža?

Xiangxue Pharmaceutical Co šiuo metu yra 1,36 % dydžio dividendų grąža.

Kada Xiangxue Pharmaceutical Co moka dividendus?

Xiangxue Pharmaceutical Co moka dividendus kas ketvirtį. Jie išmokami liepa, liepa, rugsėjis, liepa mėnesiais.

Kokia saugi yra Xiangxue Pharmaceutical Co dividendų išmokėjimas?

Xiangxue Pharmaceutical Co per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra Xiangxue Pharmaceutical Co dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 CNY. Tai atitinka 0 % dividendų grąžos procentą.

Kokiame sektoriuje yra Xiangxue Pharmaceutical Co?

Xiangxue Pharmaceutical Co priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von Xiangxue Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį Xiangxue Pharmaceutical Co dividendą nuo 2020-06-23, kurio dydis yra 0,046 CNY, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2020-06-23.

Kada Xiangxue Pharmaceutical Co paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2020-06-23.

Kokia buvo Xiangxue Pharmaceutical Co dividendų suma 2023 metais?

2023 metais Xiangxue Pharmaceutical Co išmokėjo 0 CNY dividendų.

Kokia valiuta Xiangxue Pharmaceutical Co moka dividendus?

Xiangxue Pharmaceutical Co dividendai yra mokami CNY.

Xiangxue Pharmaceutical Co Akcijų kodas	Xiangxue Pharmaceutical Co FIGI
300147:CH	BBG0018L1000
300147:CS	BBG0018R7FW3
300147:C2	BBG00F13B4V3

Padaryk geriausias savo gyvenimo investicijas fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Kursas

Akcijos kaina

Akcijų kodas300147.SZ

ISINCNE100000Y92

Xiangxue Pharmaceutical Co akcijų apyvarta, EBIT, pelnas CNE100000Y92 ·

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

Xiangxue Pharmaceutical Co Pajamų, pelno ir EBIT istorija.

Xiangxue Pharmaceutical Co Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

Xiangxue Pharmaceutical Co Akcijos Maržos CNE100000Y92 ·

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

Xiangxue Pharmaceutical Co Maržų istorija

Xiangxue Pharmaceutical Co akcijos apyvarta, EBIT, pelnas vienai akcijai CNE100000Y92 ·

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Xiangxue Pharmaceutical Co Pardavimų, pelno ir EBIT istorija vienai akcijai

Xiangxue Pharmaceutical Co akcija ir akcijų analizė

Xiangxue Pharmaceutical Co įvertinimas pagal istorinį P/E, EBIT ir P/S

Xiangxue Pharmaceutical Co akcijų skaičius CNE100000Y92 ·

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Xiangxue Pharmaceutical Co Akcijų padalijimai

Xiangxue Pharmaceutical Co akcijos dividendas CNE100000Y92 ·

Dividendas

Dividendų apžvalga

Interpretacija ir naudojimas

Investavimo strategija

Xiangxue Pharmaceutical Co Dividendų istorija

Xiangxue Pharmaceutical Co akcijų išmokėjimo koeficientas CNE100000Y92 ·

Dividendų mokėjimo rodiklis

Kas yra metinis dividendų mokėjimo rodiklis?

Kaip interpretuoti duomenis

Duomenų naudojimas investavimui

Xiangxue Pharmaceutical Co Dividendų išmokėjimo istorija

Xiangxue Pharmaceutical Co Pelno prognozės

Xiangxue Pharmaceutical Co Pelnų staigmenos

Xiangxue Pharmaceutical Co akcijos akcininkų struktūra

Xiangxue Pharmaceutical Co Valdyba ir Priežiūros taryba

Xiangxue Pharmaceutical Co Tiekimo grandinė.

Dažnai užduodami klausimai apie Xiangxue Pharmaceutical Co akciją